文献速递头颈外科

美国商业保险口咽癌患者的终生医疗费用

Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States.
PubMed 文献 · Head Neck · 2020-05-02

本研究基于Truven MarketScan商业索赔数据库,纳入2445例口咽癌患者,采用Cox生存分析估算月度生存概率,并预测分阶段终生医疗费用。

要点

  • 研究采用Cox生存分析与费用比例法预测分阶段终生费用。
  • 该费用估算基于美国商业保险人群,共2445例患者。

核心结论

  • 商业保险口咽癌患者的终生医疗费用在初始期最高,持续期次之,终末期最低。

研究设计与样本

  • 利用Truven MarketScan商业索赔与 encounter 数据库识别口咽癌患者,采用Cox生存分析估算月度生存概率,并基于死亡患者费用比例预测分阶段终生费用。
  • 研究样本为2445例美国商业保险口咽癌患者。

临床怎么用

  • 可为商业保险口咽癌患者的费用估算和资源规划提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Incidence of oropharyngeal cancer (OPC) is expected to increase but its health care cost is unknown. The purpose for this study was to estimate the phase-specific lifetime health care costs of OPC for commercially insured individuals in the United States. METHODS: We used the Truven MarketScan Commercial Claims and Encounter Database to identify our patient population. Cox survival analysis was used to estimate patients' monthly survival probabilities. We determined the ratios of the cumulative costs up to a particular survival probability and the costs from that time point to death for all subjects who died before end of the 5-year follow-up period. This relationship was then used to predict phase-specific lifetime health care costs. RESULTS: Our study included 2445 patients with OPC. The predicted phase-specific lifetime health care costs attributable to OPC were $88 872, $24 038, and $1537 in the initial, continuous, and terminal phases, respectively, among commercially insured patients.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Wu CF, Lairson DR, Dahlstrom KR, et al. Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States. Head Neck. 2020. PMID: 32359131. doi:10.1002/hed.26201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。